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Abstract 
 
Steroid sulfatase plays a pivotal role in regulating the formation of biologically active 
steroids from inactive steroid sulfates.  It is responsible for the hydrolysis of estrone 
sulfate and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone, 
respectively, both of which can be subsequently reduced to steroids with estrogenic 
properties (i.e. estradiol and androstenediol) that can stimulate the growth of tumors 
in hormone-responsive tissues of the breast, endometrium and prostate.  Hence, the 
action of steroid sulfatase is implicated in physiological processes and pathological 
conditions.  It has been five years since our group last reviewed the important role of 
this enzyme in steroid synthesis and the progress made in the development of potent 
inhibitors of this important enzyme target.  This timely review therefore concentrates 
on recent advances in steroid sulfatase research, and summarises the findings of 
clinical trials with Irosustat (BN83495), the only steroid sulfatase inhibitor that is 
being trialed in postmenopausal women with breast or endometrial cancer. 
 
Introduction 
 
Breast cancer is the most commonly diagnosed neoplasm in women in the UK, 
causing over 45,000 new cases and 12,000 deaths annually (Office for National 
Statistics, 2009). In the 75% of invasive breast cancers that express the estrogen 
receptor (ER), estrogens are key promoters of tumorigenesis (Yager & Davidson, 
2006). It is surprising, therefore, that more than two-thirds of breast cancers occur in 
postmenopausal women when the ovaries cease to produce estrogen (Pasqualini, 
2004). However, despite the 90% reduction in plasma estradiol (E2) levels that occur 
with the menopause, the tissue concentrations of estrogens in normal breast tissue of 
pre- and post-menopausal women are comparable (Geisler, 2003; van Landeghem et 
al, 1985; Thijssen et al, 1986). This reflects extragonadal biosynthesis of estrogens, 
which occurs in a number of peripheral tissues, including not only breast, but also 
adipose tissue, muscle, skin and bone (Suzuki et al, 2005). These represent the main 
sites of estrogen synthesis beyond the menopause (Simpson et al, 1999), which is 
derived from the conversion of circulating precursor C19 steroids. These include the 
androgens, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS) and 
androstenedione (Adione), which are primarily of adrenal origin (Couzinet et al, 
2001).
 
 
The importance of local breast tissue estradiol production in the pathogenesis of 
breast carcinoma is supported by numerous studies which have reported tumor tissue 
estrogen levels being 2-20 fold elevated when compared to corresponding plasma 
levels (van Landeghem et al, 1985; Vermeulen et al, 1986; Pasqualini et al, 1996). In 
fact, it has been demonstrated that in postmenopausal women, intratumoral estradiol 
levels are 2-3 fold higher than in areas considered as morphologically normal 
(Bonney et al, 1983;  Chetrite et al, 2000).  This suggests an augmented local tumoral 
biosynthesis and accumulation of these hormones which is thought to play an 
important role in the development of hormone-dependent breast cancer.  Using in 
vitro approaches, a number of authors have confirmed the ability of human breast and 
its neoplasms to locally synthesize estrogens  (Perel et al, 1980; Miller et al, 1982;  
Adams & Li, 1975; Varela & Dao, 1978) and in fact, Yue and co-workers 
demonstrated that in situ estradiol synthesis predominates over uptake from plasma in 
the maintenance of elevated intratumoral hormone concentrations (Yue et al, 1998a, 
1998b).  Although there is overwhelming evidence for intracrine mechanisms of 
estrogen synthesis and action, the issue of quantitative contribution of local synthesis 
of estrogenic steroids versus uptake from circulation, remains controversial (Haynes 
et al, 2010).  These authors found a significantly higher concentration of E2 in tumors 
versus normal tissue which correlated significantly with ER+ status.  Other alternative 
factors which can influence intra-tumoral E2 disposition, such as EST, STS and 17β-
HSD1/7, cannot be excluded.  However, the improvement in the sensitivity of the 
assay procedures may explain the discrepancy between the findings of Lønning et 
al.(2009) and those reported by Thijssen et al. (1987).  Clearly, components of both 
uptake and local synthesis are physiologically important (Yue et al. 1998a). 
 
Expression of enzymes involved in synthesis of estrogenic steroids 
 
A number of estrogen metabolizing enzymes are involved in the local synthesis of 
estrogens in breast tumors from circulating inactive steroid precursors (Figure 1.) 
Synthesis of steroids with estrogenic activity occurs via 2 main pathways: the 
aromatase and steroid sulfatase (STS) pathways. In the former, androstenedione 
(Adione) is converted to estrone (E1) by aromatase (Miller et al, 1982). The latter 
pathway utilizes inactive sulfated steroids, including estrone sulfate (E1S), as 
precursors. E1S is the predominant estrogen found in the circulation of postmenopausal 
women (Santner et al, 1984). Although biologically inactive, its long half-life (Ruder et 
al, 1972) and high serum concentrations (Noel et al, 1981; Pasqualini, 2004) is thought 
to  create a large reservoir which is utilized by steroid sulfatase (STS) for the formation 
of E1 by desulfonation. Of note, E1S, carrying a net negative charge, is hydrophilic and 
unable to cross cell membranes. It is thought that its uptake into cells involves specific 
transporter proteins, and the organic anion transport polypeptide B (OATP-B), has 
received particular attention in this respect. OATP-B (OATP2B1, SLCO2B1) has been 
reported to be expressed in both normal and neoplastic breast tissue (Al Sarakbi et al, 
2006; Alcorn et al, 2002; Pizzagalli et al, 2003; Wlcek et al, 2008).  Additionally, 
immunoreactivity of human liver-specific transporter LST-2 (OATP8, SLCO1B3) was 
reported to be a potent prognostic factor in human breast cancer (Muto et al., 2007).  
Therefore, breast tumors express the necessary machinery for the uptake and 
conversion of sulfated steroids into biologically active estrogens. Estrone 
sulfotransferase (EST), a member of the superfamily of steroid sulfotransferases, is also 
expressed in breast tissue and opposes the action of STS by sulfating El to ElS (Sasano 
et al, 2009). El, formed either through the aromatase or sulfatase pathways, is 
subsequently reduced to the biologically potent estradiol (E2), by 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1). Oxidation (inactivation) of E2 to E1 is carried out 
by 17βHSD type 2 (17βHSD2) (Figure 1). 
 
The relevance and interplay between aromatase, STS, OATP-B and 17βHSDl to 
facilitate local synthesis of estrogenic steroids within breast and other tissues, is 
detailed in several excellent reviews (Nussbaumer & Billich, 2005; Ghosh, 2007; 
Buono & Cosma, 2010; Lin et al, 2010; Bojarova & Williams, 2008; Suzuki et al, 
2009). 
  
Studies examining the expression, immunoreactivity and/or activity of the above 
proteins have revealed their importance in breast carcinoma. For example, intratumoral 
aromatase and STS mRNA levels have been shown to be significantly elevated when 
compared to adjacent non-malignant tissues (Utsumi et al, 1996; Miki et al, 2007; 
Utsumi et al, 2000;  Honma et al, 2006). Indeed, STS activity has been reported to be 
10-200 fold higher than that of aromatase in both pre- and postmenopausal breast 
cancer patients (Pasqualini et al, 1996; Chetrite et al, 2000; Santner et al, 1984). 
Additionally, STS immunoreactivity is detected more frequently in breast carcinomas 
(59-88% Suzuki et al, 2003; Tsunoda et al, 2006; Saeki et al, 1999) and compares well 
with that reported by others: 40-66.7% (Yamamoto et al 2003; Esteban et al, 1992; 
Santen et al, 1994; Lu et al, 1996; Shenton et al, 1998; Brodie et al, 2001) and it has 
been estimated that this pathway may be responsible for 10-fold greater intratumoral 
estradiol production (Santen et al, 1986). STS has also been associated with a number 
of clinicopathological parameters in breast cancer patients such as tumor size, risk of 
recurrence, poor prognosis, reduced disease free survival and disease progression, 
whereas the data for aromatase is less conclusive (Silva et al, 1989; Lipton et al, 1992; 
Miyoshi et al, 2003; Suzuki et al, 2003, Utsumi et al, 1999; Yoshimura et al, 2004) 
 
The literature also suggests a trend towards elevated OATP-B expression in malignant 
breast tissue, and higher mRNA levels of this transporter have been linked with 
increasing tumor grade (Al Sarakbi et al, 2006). Although not necessarily over-
expressed in breast cancer, several immunohistochemical studies have reported 17β-
HSDl expression in approximately 50 to 60% of breast neoplasms (Poutanen et al, 
1992; Sasano et al, 1996; Suzuki et al, 2000). Additionally, 17β-HSDl gene 
amplification and expression have been associated with poor prognosis (Gunnarsson et 
al, 2008; Oduwole et al, 2004). By contrast, 17β-HSD2 mRNA or immunoreactivity is 
frequently not detected in breast carcinomas (Suzuki et al, 2000; Gunnarsson et al, 
2001), and low expression, in conjunction with a high levels of 17β-HSD1, has 
prognostic significance and is associated with higher rates of recurrence in ER positive 
patients (Gunnarsson et al, 2001; Gunnarsson et al, 2005). From these studies it is clear 
that 17β-HSD2, by inactivating E2, protects against tumor progression in normal breast 
tissue. 
In recent years, the expression of other isoforms of 17β-HSD such as 17β-HSD7 and 
17β-HSD12 has been described in breast cancer tissue and cell lines (Haynes et al, 
2010; Day et al, 2009; Shehu et al, 2011). The relative contribution of each of these 
isoforms to intra-tumoral E2 synthesis remains to be determined.  The enzyme kinetic 
activities of each of these isoforms has not been independently determined.  Selective 
knockdown with siRNA will further highlight the contribution of each isoform. In 
addition, in contrast to 17β-HSD1/2, the prognostic significance of these recent 
isoforms remains to be assessed. 
 
 
 
 
 
 
Therapeutic relevance of steroid sulfatase 
 
 
(a) Androstenediol: the underappreciated product of the steroid sulfatase pathway 
 
 
Apart from E1, the STS pathway is also responsible for the production of another 
steroid with estrogenic properties, namely androstenediol (Adiol). DHEAS, secreted 
exclusively by the adrenal cortex (Panjari & Davis, 2007), is converted to DHEA by 
STS, which can subsequently be reduced to Adiol by 17β-HSD1. Adiol, although an 
androgen, can bind to the estrogen receptor, and has been shown to stimulate the 
proliferation of a number of ER-positive breast cancer cells in an ER-dependent 
manner (Poulin & Labrie, 1986; Aspinall et al,  2004). Despite its lower affinity for the 
ER (Poulin & Labrie, 1986), the 100-fold higher circulating concentrations of this 
hormone have led some to speculate that it may have equipotent estrogenic properties 
to E2 (Spinola et al, 1986). In vivo rodent models of carcinogen induced mammary 
carcinomas have demonstrated the ability of Adiol to stimulate tumor growth, even in 
the presence of aromatase inhibitors, confirming that this hormone does not need to be 
further aromatized to reveal its estrogenic effects (Dauvois & Labrie, 1989). Billich and 
colleagues demonstrated for the first time that inhibition of STS blocked DHEAS- 
stimulated growth of MCF-7 breast cancer cells, an effect which was not reproduced by 
concurrent treatment with aromatase inhibitors (Billich et al, 2000). This confirms that 
the STS pathway is responsible for the production of the estrogenic compound Adiol 
from DHEAS, and that this occurs in an aromatase-independent fashion. This is of 
clinical significance because in postmenopausal breast cancer patients treated with 
aromatase inhibitors, unrestrained production of Adiol can occur via the STS pathway 
and may promote tumor progression. Furthermore, Masamura et al (1995) reported that 
ER positive breast cancer cells become sensitized under very low estrogen exposure. 
Taken together, this could translate to potentiation of the estrogenic effects of Adiol in 
patients on aromatase inhibitors in whom E2 levels are virtually undetectable. Further 
support for the role of STS in utilization of DHEAS in human adipose tissue has been 
recently reported by Dalla Valle et al (2006).  These investigators found tissue-specific 
transcripts and activity of STS in human adipose tissue and corresponding expression 
of OATPs B, D and E.  In line with this, uptake plus desulfation of 
3
H-DHEAS could 
be measured, whereas sulfotransferase expression was not found.  It is interesting to 
speculate whether excessive fat may therefore provide an important source of 
estrogenic Adiol. This provides further rationale and motivation for the development of 
STS inhibitors (reviewed by  Woo,L.W et al in this issue. 2010; Reed et al, 2005) 
 
Although much in vitro and in vivo evidence exists regarding the role of DHEAS-
derived estrogenic hormones in supporting breast cancer progression, there are few 
studies investigating their importance in women. A raised serum DHEAS has been 
demonstrated in postmenopausal women with breast cancer when compared to controls 
(Aspinall et al, 2003), suggesting that increased adrenal secretion of this androgen may 
have a role in the pathogenesis of breast cancer, possibly due to its conversion to Adiol. 
Higher concentrations of DHEAS and DHEA have also been associated with an 
increased risk of breast cancer in postmenopausal women, especially in ER+/PR+ cases 
(Key et al, 2002;  Dorgan et al, 1997; Missmer et al, 2004;  Morris et al, 2001). 
 
At this junction, it is important to emphasise that the affinities of the substrates for the 
aromatase or STS are very different.  For example, the Km of androstenedione for 
aromatase is 8-10 nM whereas that of E1S or DHEAS for STS is 7-14 µM.  The 
numerical value of Km is important as it establishes an approximate value for the 
intracellular level of the substrate (Segal 1975).  There is no physiological sense in 
maintaining a substrate concentration much lower or much higher than the Km as the 
catalytic potential of the enzyme would be wasted or the enzyme would function 
inefficiently.  The median plasma concentrations of androstenedione and DHEAS in 
postmenopausal women in our study were 2-4 nM and 1-2 µM, respectively (Stanway 
et al., 2006).  These are proportional to the corresponding Km values, although the 
tissue concentrations can be much higher.  The physiological relevance of the substrate 
affinities (i.e. Km values) and the substrate concentrations is highlighted by Santner et 
al. (1984).  These authors reported that comparison of STS with aromatase activity in 
human tumors at physiological levels of substrate revealed that 10 times more E1 was 
formed from the STS pathway than the aromatase pathway.  This finding would hold 
true even more in those tumors where STS mRNA expression is significantly increased. 
 
 
b) Resistance to endocrine therapy 
 
A common problem with the available endocrine therapies is that of acquired resistance 
(Musgrove & Sutherland, 2009). There is a growing body of evidence to suggest that 
hormonal adaptations, and the emergence of alternative intratumoral estrogen 
production pathways, may contribute to this. Indeed, studies in breast cancer patients 
treated in the adjuvant setting with aromatase inhibitors or tamoxifen have 
demonstrated that those with elevated DHEAS were associated with disease 
progression (Calhoun et al, 2003; Morris et al, 2001). It is tempting to speculate that 
this may be due to increased synthesis of Adiol, although this was not investigated 
directly in these studies. DHEAS levels have also been reported to increase equally 
with 12 months of adjuvant tamoxifen and letrozole treatment, again supporting the 
notion of a compensatory increase in the production of this adrenal androgen to 
overcome the endocrine blockade (Rossi et al, 2009).  
 
Very recently, in elegant studies carried out by Chanplakorn et al (2010), it has been 
reported that neoadjuvant treatment with exemestane caused a significant increment in 
intratumoral 17β-HSDl and STS immunoreactivity, suggesting an upregulation of 
estrogen synthesizing enzymes in response to estrogen depletion. Exemestane was 
given daily at 25mg/day for 16-24 weeks to 116 Japanese postmenopausal patients with 
primary invasive ductal carcinoma.  Status of STS, EST, 17β-HSD1, ER, PR, Her2 and 
Ki67 in 49 pre- and post-exemestane specimens was evaluated by 
immunohistochemistry.  A significant increase in STS and 17β-HSD1 
immunohistological scoring following AI neoadjuvant therapy was demonstrated for 
the first time.  The authors hypothesise that this increase in STS and 17β-HSD1 may be 
a compensatory response of the breast tumors to estrogen depletion, particularly as the 
significant increment was only detected in the group associated with decreased Ki67 
labelling index.  The same researchers also demonstrated increased intratumoral 5α-
dihydrotestosterone (DHT) concentration and 17β-HSD2 expression following 
exemestane therapy (Takagi et al, 2010).  The important role of androgens in apocrine 
breast cancer is reviewed by Suzuki et al (2010). 
 
In vitro, cancer cells exposed to a long-term E2-deprived environment, adapted by up-
regulation of signalling pathways involving ERα, HER-2/neu, EGFR and IGFR.  These 
pathways signal through MAPK, PI3K and mTOR and the cross-talk between these 
pathways is believed to drive proliferation.  These pathways have also been shown to 
be activated in in vivo models of development of resistance to aromatase inhibitors by 
the group of Angela Brodie.  A combination of traztuzumab with letrozole is found to 
be superior to the aromatase inhibitor alone in these xenograft models (reviewed in: 
Santen et al. 2009). 
 
Lessons learnt from clinical trials with enzyme inhibitors 
 
Many clinical trials have now been carried out with the third-generation aromatase 
inhibitors but so far only one phase I trial with a STS inhibitor has been conducted 
(Smith & Dowsett, 2003; Coombes et al. 2004; Stanway et al. 2006).  Measurement of 
serum oestrogen concentrations by RIA, employed as a surrogate marker of the 
effectiveness of AIs, is not straight forward and in some early studies it was difficult to 
detect the real effects of aromatase inhibitors from such measurements.  More recently, 
very sensitive RIAs have been developed involving solvent extraction and 
chromatographic separation of oestrogens prior to RIA (Lonning & Ekse, 1995; 
Lonning et al, 1997).   However, a ‘gold standard’ GC-MS/MS method has now been 
developed for the measurement of serum oestrogens (Sundaram et al, 2003).  Using 
highly sensitive RIAs, there is no doubt that in most cases, plasma or serum levels of 
E1 and E2 are suppressed to below the limits of quantitation of the assays by third-
generation aromatase inhibitors (Geisler et al, 2002).   For E1S, while levels has been 
found to be suppressed by >98% by third-generation aromatase inhibitors, the 
geometric mean E1S concentrations after 16 weeks treatment with letrozole was 
3.9pmol/l (Geisler et al, 2008).  As most patients treated with aromatase inhibitors will 
eventually progress, it is possible that the low levels of E1S still detectable may 
contribute to tumor cells becoming resistant to this form of therapy.   Although these 
plasma levels of E1S are very low it is now well documented that breast cancer cells, 
grown in an estrogen-deprived environment, can become sensitive to extremely low 
estrogen concentrations (Masamura et al, 1995). 
 
In contrast to the problems associated with measuring aromatase activity in patients, the 
effects of STS inhibitors can be readily assessed.   STS is present in peripheral blood 
lymphocytes (PBLs) and the extent and duration of STS inhibition can be readily 
determined by measuring its activity in these cells (Purohit et al, 1995).   In the first 
ever phase I trial of Irosustat (STX64, BN83495), STS activity, as measured in PBLs, 
was suppressed by >95% at the 5 mg/day and 20 mg/day doses tested (Stanway et al,  
2006).   This level of STS inhibition was associated with moderate, but significant, 
reductions in the median concentrations of E1 (57-76%), E2 (38-39%) and testosterone 
(27-30%).   In addition, the median concentration of the steroid with oestrogenic 
properties, Adiol, decreased by 70-74%.  Unexpectedly, serum Adione median 
concentrations also decreased by 62-72% indicating that, at least in postmenopausal 
women, a significant proportion of this steroid is derived from the peripheral 
conversion of DHEAS. The results from the STX64 phase I trial therefore show that 
while median serum concentrations of Adiol, Adione and E1 all decreased by 
approximately 70%, the reductions for testosterone and E2 were less, at about 30%.  
Similar results were obtained in a second dose-escalation study of Irosustat in 
postmenopausal women with ER+ve metastatic breast cancer (Coombes et al, 2009).  
Patients were recruited into 5 sequential dose cohorts (1, 5, 20, 40 and 80mg).  The 
optimum biological dose was determined to be 40mg.  At this dose, Adiol 
concentrations decreased by 34-74% and E2 concentrations decreased by 7-27%.  
Disease stabilization of 7-13 months was demonstrated in 3 of 14 patients who received 
>3 months treatment.  Considering that the aromatase pathway of estrogen synthesis 
was not inhibited in these patients, the reduction in serum hormone concentrations and 
the disease stabilization obtained in some patients, were very encouraging. Currently, 
Phase II studies in women with endometrial cancer are in progress (www.ipsen.com).  
Endometrial cancer is the most common gynecological malignancy with an unmet need 
for better therapy.  When measured by validated mass spectrometry assays, circulating 
levels of E1, E2 and E1S were found to be significantly higher in women with 
endometrial cancer when compared with unaffected controls.  Enhanced E2 synthesis in 
tumors was supported by increased expression of STS and 17β-HSD1 in peritumoral 
normal endometrium. The expression of these enzymes was significantly increased in 
tumors (Lepine et al, 2010) again highlighting the importance of this pathway for the 
synthesis of estrogenic steroids. 
 
Summary and Future perspectives 
 
Steroid sulfates are now acknowledged to have an important role as prohormones for 
the formation of biological active steroids. In recent years, a wealth of evidence has 
emerged, particularly from the Japanese groups of H. Sasano, T. Suzuki and N. Harada, 
strongly supporting the important role of STS expression and immunoreactivity in 
breast cancer progression and in the development of resistance to endocrine therapy. 
Although much work has been carried out to characterize the expression of the main 
enzymes involved in the synthesis of estrogenic steroids breast and other cancers, most 
studies have investigated these genes in isolation. It is essential to study the 
simultaneous expression of these genes, and compare this to the level in normal tissue, 
in an attempt to improve our understanding of how these proteins are expressed in 
concert and how their levels may be altered in the tumor microenvironment. 
Information from such studies may also facilitate the identification and selection of 
patients who are most likely to benefit from treatment with STS inhibitors.  In addition, 
important structural information derived from the x-ray crystallographic studies of STS 
pioneered by D. Ghosh and co-workers, will aid to design novel inhibitors. 
 
Currently, Phase I clinical trials of Irusustat are in progress in women with advanced 
breast or endometrial cancer. Additional phase II/III trials will be required to confirm 
whether STS inhibitors are to have a place in the armory against breast and other 
hormone-dependent cancers.  Future trials of STS inhibitors in combination with 
aromatase inhibitors, or other agents including dual-target inhibitors (Woo et al, 2010), 
will be required to determine whether such combinations offer any advantage over the 
use of single-agent therapy.  The trend in breast cancer therapy is towards personalised 
medicine.  Therefore, patient enrichment by evaluation of the expression of aromatase, 
STS and other enzymes and receptors in tumor tissue by immunostaining and/or 
combined laser capture microdissection/qRT-PCR will be essential.  These techniques 
have been successfully developed and thoroughly validated in the laboratories of Drs. 
Sasano and Harada (Sasano et al. 2009). 
 
Although this review has focused on the potential use of STS inhibitors for the 
treatment of hormone-dependent cancers, they could also have therapeutic efficacy in a 
number of other conditions that still remain to be explored.   STS is ubiquitously 
distributed throughout the body and may have important roles in regulating the 
production of androgens in a number of skin conditions (Reed et al, 2008) and part of 
the immune response (Rook et al. 1994; Reed et al. 2003).   In addition, little is known 
about the role of STS in normal male and female reproduction although there is 
evidence that STS inhibitors could be effective in conditions such as endometriosis 
(Purohit et al. 2008).   With the advent of potent STS inhibitors it will, for the first time, 
be possible to explore their therapeutic potential in a wide range of normal and 
abnormal conditions. 
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Fig. 1. Pathways of local synthesis of estrogenic steroids in neoplastic breast tissue.  
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